Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Panacea Life Sciences HoldingsPLSH -2.17% Revenue per Share is $0.04 as of Sep. 2025. The stock has 10 warning signs investors should review. Among 903 Drug Manufacturers companies, Panacea Life Sciences Holdings ranks worse than 94.68% on this metric.
Panacea Life Sciences Holdings's revenue per share for the
three
months ended in Sep. 2025 was $0.00.
Panacea Life Sciences Holdings's revenue per share for the trailing twelve months (TTM) ended in Sep. 2025 was $0.04.
Warning Sign:
Panacea Life Sciences Holdings Inc revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Panacea Life Sciences Holdings was -57.00% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -29.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Panacea Life Sciences Holdings's Revenue per Share or its related term are showing as below:
PLSH'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -29.7 Med: -29.7 Max: -29.7
Current: -29.7
During the past 4 years, Panacea Life Sciences Holdings's highest 3-Year average Revenue Per Share Growth Rate was -29.70% per year. The lowest was -29.70% per year. And the median was -29.70% per year.
PLSH's 3-Year Revenue Growth Rate is ranked worse than 94.68% of 903
companies
in the Drug Manufacturers industry
Industry Median: 3.8
vs PLSH: -29.70
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Panacea Life Sciences Holdings Revenue per Share Related Terms
Panacea Life Sciences Holdings Revenue per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panacea Life Sciences Holdings Revenue per Share Chart
PLSH vs SHPH, SKYI, CPMD: Revenue per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Panacea Life Sciences Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panacea Life Sciences Holdings PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Panacea Life Sciences Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where Panacea Life Sciences Holdings's PS Ratio falls into.
Panacea Life Sciences Holdings Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panacea Life Sciences Holdings (PLSH) has a Revenue per Share of $0.04 as of Sep. 2025. Revenue per share equals the per-share value of a company's sales. View historical data on Panacea Life Sciences Holdings and its competitors. According to the industry distribution chart, Panacea Life Sciences Holdings ranks #855 out of 903 companies in the Drug Manufacturers industry, placing it in the top 94.7%.
Is Panacea Life Sciences Holdings' Revenue per Share too high?
Panacea Life Sciences Holdings' current Revenue per Share is $0.04. The Drug Manufacturers industry median Revenue per Share is 3.80. Panacea Life Sciences Holdings' value of $0.04 is 98.9% below this industry median. Based on the distribution chart, Panacea Life Sciences Holdings ranks #855 out of 903 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Panacea Life Sciences Holdings' Revenue per Share compare to SHPH and SKYI?
According to the Drug Manufacturers industry distribution chart, Panacea Life Sciences Holdings ranks #855 out of 903 companies for Revenue per Share. This places Panacea Life Sciences Holdings in the lower half of its industry. The industry median Revenue per Share is 3.80. Panacea Life Sciences Holdings' value of $0.04 is 98.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Drug Manufacturers company?
The median Revenue per Share among Drug Manufacturers companies is 3.80, based on 903 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Panacea Life Sciences Holdings's current Revenue per Share of $0.04 is 98.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Panacea Life Sciences Holdings and its competitors. For the Drug Manufacturers industry, the median Revenue per Share is 3.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Panacea Life Sciences Holdings's current Revenue per Share is $0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Life Sciences Holdings stock overvalued right now?
Panacea Life Sciences Holdings (PLSH) has a current Revenue per Share of $0.04. The current Revenue per Share is $0.04 and 98.9% below the Drug Manufacturers industry median of 3.80. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Panacea Life Sciences Holdings (PLSH), the current Revenue per Share is $0.04 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Panacea Life Sciences Holdings Inc is a holding company organized as a plant-based natural health ingredient and product company, specializing in the development, manufacturing, research, and distribution of products and rapidly growing natural health and wellness market segment for both humans and animals. The company also offers the purest natural remedies within its branded product lines for every aspect of life: PANA Health, PANA Beauty, PANA Sport, PANA Pet, PANA Pure and PANA Life.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLSH has been successfully added to your 
